Control of HIV-1 infection by soluble factors of the immune response.
about
WFDC1/ps20 is a novel innate immunomodulatory signature protein of human immunodeficiency virus (HIV)-permissive CD4+ CD45RO+ memory T cells that promotes infection by upregulating CD54 integrin expression and is elevated in HIV type 1 infectionInsights into Soluble Toll-Like Receptor 2 as a Downregulator of Virally Induced InflammationSoluble factors from T cells inhibiting X4 strains of HIV are a mixture of β chemokines and RNases.Novel function of prothymosin alpha as a potent inhibitor of human immunodeficiency virus type 1 gene expression in primary macrophagesPhosphatidylcholine-specific phospholipase C activation is required for CCR5-dependent, NF-kB-driven CCL2 secretion elicited in response to HIV-1 gp120 in human primary macrophages.Self-protection of individual CD4+ T cells against R5 HIV-1 infection by the synthesis of anti-viral CCR5 ligands.Autocrine production of beta-chemokines protects CMV-Specific CD4 T cells from HIV infectionWhich Antibody Functions are Important for an HIV Vaccine?Quantification of the relative importance of CTL, B cell, NK cell, and target cell limitation in the control of primary SIV-infectionDendritic cells exposed to MVA-based HIV-1 vaccine induce highly functional HIV-1-specific CD8(+) T cell responses in HIV-1-infected individuals.Increased levels of human beta-defensins mRNA in sexually HIV-1 exposed but uninfected individualsSpatial heterogeneity and peptide availability determine CTL killing efficiency in vivo.Molecular profiling of cytomegalovirus-induced human CD8+ T cell differentiation.beta-Chemokine production by neural and glial progenitor cells is enhanced by HIV-1 Tat: effects on microglial migration.Induction of immunity to human immunodeficiency virus type-1 by vaccination.B cell responses to HIV-1 infection and vaccination: pathways to preventing infection.Genetic variation in the CCL18-CCL3-CCL4 chemokine gene cluster influences HIV Type 1 transmission and AIDS disease progression.Is developing an HIV-1 vaccine possible?The CD8-derived chemokine XCL1/lymphotactin is a conformation-dependent, broad-spectrum inhibitor of HIV-1.Lack of protection following passive transfer of polyclonal highly functional low-dose non-neutralizing antibodiesProthymosin α variants isolated from CD8+ T cells and cervicovaginal fluid suppress HIV-1 replication through type I interferon induction.Noninfectious papilloma virus-like particles inhibit HIV-1 replication: implications for immune control of HIV-1 infection by IL-27.Discovery of another anti-HIV protein in the search for the CD8+ cell anti-HIV Factor.Noncytolytic CD8+ Cell Mediated Antiviral Response Represents a Strong Element in the Immune Response of Simian Immunodeficiency Virus-Infected Long-Term Non-Progressing Rhesus Macaques.Pathogen-specific T cell depletion and reactivation of opportunistic pathogens in HIV infection.Gene therapy progress and prospects: novel gene therapy approaches for AIDS.Initial HIV-1 antigen-specific CD8+ T cells in acute HIV-1 infection inhibit transmitted/founder virus replicationStrategies for eliciting HIV-1 inhibitory antibodiesPlatelet Factor 4 Inhibits and Enhances HIV-1 Infection in a Concentration-Dependent Manner by Modulating Viral AttachmentProfound CD4+/CCR5+ T cell expansion is induced by CD8+ lymphocyte depletion but does not account for accelerated SIV pathogenesis.Effector memory T cell responses are associated with protection of rhesus monkeys from mucosal simian immunodeficiency virus challenge.Can non-lytic CD8+ T cells drive HIV-1 escape?Induction of a Soluble Anti-HIV-1 factor (s) with IFN-γ, IL-10, and β-Chemokine Modulating Activity by an Influenza-Bacterial Polyantigenic Mixture.Thymosin alpha 1 and HIV-1: recent advances and future perspectives.Induction of multifunctional human immunodeficiency virus type 1 (HIV-1)-specific T cells capable of proliferation in healthy subjects by using a prime-boost regimen of DNA- and modified vaccinia virus Ankara-vectored vaccines expressing HIV-1 Gag cHIV-1 infection suppresses expression of host cell cycle-associated gene PDS5A.Notwithstanding Circumstantial Alibis, Cytotoxic T Cells Can Be Major Killers of HIV-1-Infected Cells.Analysis of the CD8+ T cell anti-HIV activity in heterologous cell co-cultures reveals the benefit of multiple HLA class I matches.How is the effectiveness of immune surveillance impacted by the spatial distribution of spreading infections?Thymosin α 1 potentiates the release by CD8(+) cells of soluble factors able to inhibit HIV-1 and human T lymphotropic virus 1 infection in vitro.
P2860
Q24657262-EB11820A-57F9-46B7-9146-35B811E9FD7AQ26741112-206FE7C5-C91A-425A-8B41-567DF1017CB6Q30427403-0BB25F92-1744-4B8A-899F-6E15C2BD9D29Q30445480-38A0327A-5680-4B22-AF79-FD393E7BE361Q33315307-672CD87F-9A93-4CBC-8220-7B75AAFFCF1FQ33378492-920D10EC-7D27-46B8-9529-D2EB36AD6E8CQ33513965-C5639A2C-7973-40A1-A5E3-8C02CDE53522Q33772637-A072473C-C838-4B8B-A839-B06ECCA529FBQ33847798-E1130019-EE80-4689-89A3-B1FE23507428Q33916776-26F39584-9FF7-43A4-82DC-78E4EFBA26B2Q34020111-591849E7-8550-4DFA-BA5D-364B24F4E0F5Q34212428-C8402C1C-CD5C-49DC-8915-7953C63BFED4Q34245351-E4D6E3D3-E06D-4110-A011-B106BDE1008EQ34356438-156395EF-D9CD-474E-8F1D-4B74542FCFA9Q34540645-27576907-5B5E-477F-BBBF-346FEC8AF664Q34645502-55BFBA33-97A9-4CA4-87EE-E2AC8D4684BCQ34658462-CCB956E7-5423-4C30-938B-E27CD6A06F12Q35043547-36F1B2AD-CEF2-41BA-A56A-50BC04CF9CBCQ35079838-884BAE60-74DA-4B23-8217-BED50BB1E413Q35167400-1B86ABEA-0B31-4828-8047-96A8B3202570Q35588204-E30E648F-DF04-468F-B26F-52E9501F69C5Q35642774-ED8605F9-C241-4A64-BE50-06849390565AQ35818772-E45D6DF8-1958-41D8-BFEA-90CA6BC3A275Q35836048-64DEA5F7-0B33-4F1B-B94B-8AD47AD5C082Q35947091-392534C4-18A7-423E-A068-014610E467ACQ36036704-66C5ED67-8EAB-4123-B717-1728A06C1C6CQ36086631-72DFF2D7-F9D7-463C-B591-1CCA5AC412BAQ36452155-897E63D8-B316-48F1-83D3-BEB07BD1901CQ37062259-C704D971-3DE7-476B-9967-F1F4118EA117Q37273233-D60F397D-BFEB-4326-811E-1A7CE5668237Q37287080-1FEB5880-8DEE-4923-9AD4-7C67E4B1177BQ37308724-976ABE65-2A54-4DE2-8432-FE2A6F7C750BQ37375957-F76CEFD0-A002-44C2-AF2C-2CDEBF8A506EQ38768132-76C35F95-9F20-468D-9C5A-A41DA7283A24Q39028785-CAFD3BFF-F4DB-483D-A871-DBCA36890C09Q39484912-D79E4D36-A811-450E-982E-CB3945CA3D2BQ39735439-DF3BBF26-097B-4C83-B591-A2D64852AC29Q40111950-5A0C1333-3179-4359-9B98-67DFCEE2EF4EQ41119839-6A95549A-6128-4B0F-89B8-01253CFE7A6DQ41148526-3F56B2F6-128F-4EDB-A922-A2D2D1A904F1
P2860
Control of HIV-1 infection by soluble factors of the immune response.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Control of HIV-1 infection by soluble factors of the immune response.
@ast
Control of HIV-1 infection by soluble factors of the immune response.
@en
type
label
Control of HIV-1 infection by soluble factors of the immune response.
@ast
Control of HIV-1 infection by soluble factors of the immune response.
@en
prefLabel
Control of HIV-1 infection by soluble factors of the immune response.
@ast
Control of HIV-1 infection by soluble factors of the immune response.
@en
P2860
P356
P1476
Control of HIV-1 infection by soluble factors of the immune response.
@en
P2093
Anthony L DeVico
P2860
P2888
P304
P356
10.1038/NRMICRO878
P407
P50
P577
2004-05-01T00:00:00Z